BI Asset Management Fondsmaeglerselskab A S Has $1.71 Million Stake in Kenvue Inc. (NYSE:KVUE)

BI Asset Management Fondsmaeglerselskab A S lifted its position in Kenvue Inc. (NYSE:KVUE - Free Report) by 45.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 79,844 shares of the company's stock after buying an additional 24,988 shares during the quarter. BI Asset Management Fondsmaeglerselskab A S's holdings in Kenvue were worth $1,705,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in KVUE. Grove Bank & Trust lifted its position in shares of Kenvue by 438.4% in the fourth quarter. Grove Bank & Trust now owns 1,163 shares of the company's stock valued at $25,000 after buying an additional 947 shares during the last quarter. Geneos Wealth Management Inc. acquired a new stake in Kenvue during the 4th quarter valued at $29,000. SRS Capital Advisors Inc. boosted its position in Kenvue by 67.4% during the fourth quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company's stock worth $30,000 after purchasing an additional 571 shares during the period. Fortitude Family Office LLC boosted its stake in shares of Kenvue by 106.6% in the fourth quarter. Fortitude Family Office LLC now owns 1,506 shares of the company's stock valued at $32,000 after buying an additional 777 shares during the period. Finally, Versant Capital Management Inc increased its stake in Kenvue by 300.8% during the 4th quarter. Versant Capital Management Inc now owns 1,920 shares of the company's stock worth $41,000 after acquiring an additional 1,441 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Trading Up 1.2 %

Shares of KVUE traded up $0.28 during mid-day trading on Friday, reaching $23.03. 22,249,585 shares of the company were exchanged, compared to its average volume of 17,101,629. Kenvue Inc. has a 52 week low of $17.67 and a 52 week high of $24.46. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. The business has a 50 day simple moving average of $23.01 and a two-hundred day simple moving average of $22.42. The stock has a market capitalization of $44.19 billion, a PE ratio of 43.45, a PEG ratio of 2.62 and a beta of 1.02.

Kenvue (NYSE:KVUE - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The company reported $0.26 EPS for the quarter, hitting the consensus estimate of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. On average, analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, May 28th. Investors of record on Wednesday, May 14th will be issued a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.56%. The ex-dividend date is Wednesday, May 14th. Kenvue's dividend payout ratio is currently 154.72%.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on KVUE shares. Canaccord Genuity Group upped their price objective on shares of Kenvue from $24.00 to $29.00 and gave the stock a "buy" rating in a research report on Wednesday, March 5th. Royal Bank of Canada reaffirmed a "sector perform" rating and issued a $24.00 target price on shares of Kenvue in a report on Monday, February 3rd. Citigroup boosted their price target on Kenvue from $21.00 to $22.00 and gave the stock a "neutral" rating in a report on Monday, April 14th. Barclays dropped their price objective on Kenvue from $23.00 to $22.00 and set an "equal weight" rating for the company in a research report on Monday, April 14th. Finally, Redburn Atlantic began coverage on Kenvue in a research note on Thursday, April 10th. They set a "neutral" rating and a $23.50 target price for the company. Eight investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $24.42.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.